In supporting our novel finding on in vitro oxidative effects of 10 analogue, it was determined that most glioblastomas overexpressed ROS-degrading enzyme peroxiredoxin 4 (PRDX4) and suggested that pharmaceutical PRDX4 inactivation effectively kills the cancer cells by increasing ROS levels [10]. Here, PRDX4 is linked to glioblastoma.